

# Runs of homozygosity (ROH) reveal that segmental-UPD occurs as a result of recombination mediated repair of genomic imbalance

Andrea L. Penton<sup>1</sup>, Stuart Schwartz<sup>2</sup>, Jim Tepperberg<sup>2</sup>, Peter Papenhausen<sup>2</sup>

<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>2</sup>Laboratory Corporation of America Holdings®, RTP, NC

## INTRODUCTION


Whole chromosome UPD results from correction of trisomy and monosomy during embryogenesis. In contrast, segmental UPD (segUPD) is localized to specific chromosomal regions and the etiology and risks are not well understood. We show that segUPD occurs secondarily to recombination mediated selection driven repair of distinct genomic imbalances including deletions, derivative chromosomes and inverted duplication/deletions. Although the genetic lesion may be “repaired”, segUPD is associated with residual clinical risks.

## METHODS

The Affymetrix Cytoscan HD single nucleotide polymorphism (SNP) array was used to detect runs of homozygosity (ROH) associated with UPD. Cases were collected using criteria of positive UPD testing results, evidence of prior genetic abnormality located at the location of the ROH, mosaicism for the ROH, or ROH associated with a contiguous triplication.

## RESULTS

65 cases of terminal segUPD were identified in prenatal, constitutional and product of conception testing




- 26 Beckwith-Wiedemann syndrome cases at 11p
- 15 cases with adjacent triplication
- 24 additional cases including 5 indicated in chart below and in figures 1 to 5

Case	SegUPD	ROH (Mb)	Source/Age	Indication
1	1pter->p36.13	16.32	AF	*NIPT: terminal del(1)(p36.23), dup(1)(p36.23p36.22)
2	1pter->p36.22	9.39	PB/9.3yr	Multiple congenital anomalies: der(1)(1;17) prior amniotic fluid analysis
5	10q26.13->qter	11.12	PB/Newborn	*CVS: del(10)(q26->qter)
21	15q13.3->q15.2 (15%) 15q15.2->q22.31 (45%) 15q22.31->qter (75%)	71.24	PB/12yr	Short stature, developmental delay
24	21q21.1->q22.2* (40%)	24.38	PB/29yr	Possible trisomy, developmental disorder of scholastic skills

\*No clinical abnormalities observed  
\* seg-UPD likely extending to terminus of 21q  
PB=peripheral blood AF=amniotic fluid

Figure 1

Case 5: CVS reveals a FISH confirmed terminal deletion of 10q26.13->qter that is replaced with 11.12 Mb segUPD mat in newborn



Paternal exclusions indicate segUPDmat




Figure 4

Case 24: PB from 29 yr old male reveals partial correction of der(21)t(12;21)(p11.22;q22.2) cell line with likely segUPD 21 diploid cell line





Figure 2

Case 1: Routine NIPT screening detects complex genomic rearrangement (CGR): terminal deletion 1pter->p36.23 and contiguous duplication 1p36.23p36.22 (brackets)



Retention of CGR in placenta but replacement of CGR in amniotic fluid with terminal segUPD mat that extends proximally of CGR at 1p36.13 (arrow)





Figure 3

Case 2: Analysis of amniotic fluid cultures reveal a de novo der(1)t(1;17) in 21.4 week fetus with choroid plexus cysts



Replacement of der(1) with terminal 9.4 Mb segUPD from 1pter->p36.22 in PB from 9 yr old girl with global developmental delay, hearing impairment, autism spectrum disorder, precocious puberty, ependymal cyst




Figure 5

Case 21: PB from 12 yr old male shows evidence of multiple deletion repair lines

Cell lines initiated at different mitotic recombination sites (allele track, arrows). Interstitial deletion (smooth signal track, bracket) is still present in 25% of cells and allele track shows that 75% of cells are homozygous at region of deletion.





Figure 6

Model of mitotic inter-homologue sister chromatid mitotic recombination



## CONCLUSION

- SegUPD occurs secondarily to recombination mediated selection driven repair of distinct genomic imbalances
- NIPT, CVS, and amniotic fluid analyses suggest the incidence of segUPD mediated correction is underestimated
- Although the genetic lesion may be corrected there may be clinical risks:
  - The early presence of the imbalance may interfere with development
  - New imbalance may be created
  - The imbalance may still be present in some tissues
  - Autosomal recessive mutation allele pairing may occur
  - Imprinting defects
  - In some cases, this may explain the etiology of clinical phenotypes undetected by routine microarray and WES studies